| Recruiting | A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Manage NCT05621291 | National Cancer Institute (NCI) | N/A |
| Not Yet Recruiting | CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adult NCT07328503 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | A Study of Inotuzumab and Blinatumomab in People With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia NCT07313852 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy NCT06579469 | St. Jude Children's Research Hospital | — |
| Recruiting | CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT NCT07441291 | Peking University People's Hospital | Phase 3 |
| Recruiting | KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia NCT07246707 | Zhejiang University | Phase 1 |
| Recruiting | Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL) NCT06785324 | University of Chicago | N/A |
| Not Yet Recruiting | JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia NCT06902025 | He Huang | N/A |
| Recruiting | JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia NCT06689917 | Tongji Hospital | N/A |
| Recruiting | Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL NCT07244406 | Hebei Senlang Biotechnology Inc., Ltd. | Phase 2 |
| Recruiting | The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors NCT06911710 | Tianjin Medical University General Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post All NCT06658938 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Not Yet Recruiting | The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation NCT06504186 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia NCT06678282 | Shenzhen Genocury Biotech Co., Ltd. | N/A |
| Recruiting | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or R NCT05442515 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Unknown | Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL NCT05639179 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1 / Phase 2 |
| Withdrawn | Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL NCT05571540 | Kunming Hope of Health Hospital | Phase 1 / Phase 2 |
| Completed | Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL NCT05350787 | Zhejiang University | Phase 1 |
| Unknown | Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL NCT05350852 | Zhejiang University | Phase 1 |
| Recruiting | a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL NCT04781634 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With R NCT04512716 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Unknown | Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leu NCT04792593 | Hebei Senlang Biotechnology Inc., Ltd. | N/A |
| Unknown | Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia NCT04723901 | Shenzhen University General Hospital | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia NCT04546893 | Hebei Senlang Biotechnology Inc., Ltd. | N/A |
| Unknown | Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia NCT04546906 | Hebei Senlang Biotechnology Inc., Ltd. | N/A |
| Recruiting | CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) NCT04318678 | St. Jude Children's Research Hospital | Phase 1 |
| Active Not Recruiting | Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL NCT04499573 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 1 / Phase 2 |
| Completed | Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL NCT03751709 | Cedars-Sinai Medical Center | Phase 1 |
| Completed | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies NCT04088890 | Matthew Frank | Phase 1 |
| Completed | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD NCT03448393 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies NCT02328014 | Acerta Pharma BV | Phase 1 / Phase 2 |
| Completed | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing NCT02315612 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Multi-centric Study NCT01219816 | Nantes University Hospital | Phase 2 |
| Completed | Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphobla NCT01209286 | Amgen Research (Munich) GmbH | Phase 2 |
| Completed | Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lym NCT01290120 | Northern Italy Leukemia Group | Phase 2 |